Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | IDO1 | P14902 | 15/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3018553 | 0.85 | IDO1 (0.55) | KDM4EIDO1KMT2AMEN1LMNA | |
| SCHEMBL613546 | 0.84 | KDM4E (0.67) | KDM4EIDO1KMT2AMEN1LMNA | |
| SCHEMBL17023339 | 0.83 | IDO1 (0.52) | KDM4EIDO1KMT2AMEN1LMNA | |
| SCHEMBL29781763 | 0.82 | KMT2A (0.48) | KDM4EKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL17023318 | 0.82 | KMT2A (0.48) | KDM4EKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL24144439 | 0.82 | IDO1 (0.52) | KDM4EIDO1KMT2AMEN1LMNA | |
| SCHEMBL29781817 | 0.81 | KDM4E (1.00) | KDM4EIDO1KMT2AALDH1A1 | |
| SCHEMBL12481275 | 0.81 | KDM4E (1.00) | KDM4EIDO1KMT2AALDH1A1 | |
| SCHEMBL18576521 | 0.81 | KDM4E (0.59) | KDM4EIDO1KMT2AMEN1LMNA | |
| SCHEMBL29164497 | 0.78 | HTT (0.64) | KDM4EIDO1KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301336-B2 | Phosphonate compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190085005-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-10100072-B2 | Phosphonate compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-10000516-B2 | Phosphonate compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9663543-B2 | Phosphonate compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663543-B2 | Phosphonate compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20170057983-A1 | Phosphonate Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| WO-2017035357-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| EP-3110806-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| WO-2015130845-A9 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2015130845-A9 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2015130845-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015130845-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, CFH, TFPI | KDM4E 4614/4885IDO1 4775/4885KMT2A 4590/4885 |
| US-10100072-B2 | Phosphonate compounds for treatment of complement mediated disorders | CFD, TFPI, C1QBP | KDM4E 4741/4885IDO1 3751/4885KMT2A 4732/4885 |
| US-20170057983-A1 | Phosphonate Compounds for Treatment of Medical Disorders | CFD, TFPI, CFH | KDM4E 4632/4885IDO1 4806/4885KMT2A 4696/4885 |
| US-10301336-B2 | Phosphonate compounds for treatment of complement mediated disorders | CFD, TFPI, C1QBP | KDM4E 4741/4885IDO1 3751/4885KMT2A 4732/4885 |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C1QBP | KDM4E 4741/4885IDO1 3751/4885KMT2A 4732/4885 |
| US-20190085005-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C1QBP | KDM4E 4741/4885IDO1 3751/4885KMT2A 4732/4885 |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C1QBP | KDM4E 4741/4885IDO1 3751/4885KMT2A 4732/4885 |
| US-10000516-B2 | Phosphonate compounds for treatment of medical disorders | CFD, TFPI, CFH | KDM4E 4632/4885IDO1 4806/4885KMT2A 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.